
## Salomé Soares de Pinho

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4063880/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Glycans as shapers of tumour microenvironment: A sweet driver of Tâ€cellâ€mediated antiâ€ŧumour immune response. Immunology, 2023, 168, 217-232.	2.0	10
2	Altered IgG glycosylation at COVIDâ€19 diagnosis predicts disease severity. European Journal of Immunology, 2022, 52, 946-957.	1.6	26
3	Glycans as a key factor in self and nonself discrimination: impact on the breach of immune tolerance. FEBS Letters, 2022, 596, 1485-1502.	1.3	14
4	Neutralizing Anti-Granulocyte Macrophage-Colony Stimulating Factor Autoantibodies Recognize Post-Translational Glycosylations on Granulocyte Macrophage-Colony Stimulating Factor Years Before Diagnosis and Predict Complicated Crohn's Disease. Gastroenterology, 2022, 163, 659-670.	0.6	18
5	The Role of Glycans in Chronic Inflammatory Gastrointestinal and Liver Disorders and Cancer. , 2021, , 444-470.		0
6	SARS-CoV-2 Infection Drives a Glycan Switch of Peripheral T Cells at Diagnosis. Journal of Immunology, 2021, 207, 1591-1598.	0.4	4
7	Protein Mannosylation as a Diagnostic and Prognostic Biomarker of Lupus Nephritis: An Unusual Glycan Neoepitope in Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2021, 73, 2069-2077.	2.9	15
8	The Role of Glycosylation in Inflammatory Diseases. Advances in Experimental Medicine and Biology, 2021, 1325, 265-283.	0.8	5
9	Bringing to Light the Risk of Colorectal Cancer in Inflammatory Bowel Disease: Mucosal Glycosylation as a Key Player. Inflammatory Bowel Diseases, 2021, , .	0.9	3
10	Protein Glycosylation as a Diagnostic and Prognostic Marker of Chronic Inflammatory Gastrointestinal and Liver Diseases. Gastroenterology, 2020, 158, 95-110.	0.6	95
11	Glycans as Immune Checkpoints: Removal of Branched N-glycans Enhances Immune Recognition Preventing Cancer Progression. Cancer Immunology Research, 2020, 8, 1407-1425.	1.6	33
12	Genetic Variants of the MGAT5 Gene Are Functionally Implicated in the Modulation of T Cells Glycosylation and Plasma IgG Glycome Composition in Ulcerative Colitis. Clinical and Translational Gastroenterology, 2020, 11, e00166.	1.3	20
13	A [Glyco]biomarker that Predicts Failure to Standard Therapy in Ulcerative Colitis Patients. Journal of Crohn's and Colitis, 2019, 13, 39-49.	0.6	18
14	Metabolic control of T cell immune response through glycans in inflammatory bowel disease. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E4651-E4660.	3.3	77
15	Glycosylation in cancer: Selected roles in tumour progression, immune modulation and metastasis. Cellular Immunology, 2018, 333, 46-57.	1.4	157
16	Glycans as Key Checkpoints of T Cell Activity and Function. Frontiers in Immunology, 2018, 9, 2754.	2.2	109
17	Glycans as critical regulators of gut immunity in homeostasis and disease. Cellular Immunology, 2018, 333, 9-18.	1.4	27
18	Glycans as Regulatory Elements of the Insulin/IGF System: Impact in Cancer Progression. International Journal of Molecular Sciences, 2017, 18, 1921.	1.8	20

## Salomé Soares de Pinho

#	Article	IF	CITATIONS
19	Cadherins Glycans in Cancer: Sweet Players in a Bitter Process. Trends in Cancer, 2016, 2, 519-531.	3.8	31
20	Studying T Cells N-Glycosylation by Imaging Flow Cytometry. Methods in Molecular Biology, 2016, 1389, 167-176.	0.4	4
21	<i>O</i> -mannosylation and <i>N</i> -glycosylation: two coordinated mechanisms regulating the tumour suppressor functions of E-cadherin in cancer. Oncotarget, 2016, 7, 65231-65246.	0.8	35
22	OXPHOS dysfunction regulates integrin-Â1 modifications and enhances cell motility and migration. Human Molecular Genetics, 2015, 24, 1977-1990.	1.4	35
23	Glycosylation in cancer: mechanisms and clinical implications. Nature Reviews Cancer, 2015, 15, 540-555.	12.8	2,147
24	E-Cadherin Glycosylation in Cancer. , 2015, , 977-982.		0
25	Dysregulation of T cell receptor N-glycosylation: a molecular mechanism involved in ulcerative colitis. Human Molecular Genetics, 2014, 23, 2416-2427.	1.4	55
26	E-cadherin Glycosylation in Cancer. , 2014, , 1-6.		1
27	Pancreatic Cancer Cell Glycosylation Regulates Cell Adhesion and Invasion through the Modulation of $\hat{I}\pm 2\hat{I}^21$ Integrin and E-Cadherin Function. PLoS ONE, 2014, 9, e98595.	1.1	55
28	Gastric cancer: adding glycosylation to the equation. Trends in Molecular Medicine, 2013, 19, 664-676.	3.5	95
29	E-cadherin and adherens-junctions stability in gastric carcinoma: Functional implications of glycosyltransferases involving N-glycan branching biosynthesis, N-acetylglucosaminyltransferases III and V. Biochimica Et Biophysica Acta - General Subjects, 2013, 1830, 2690-2700.	1.1	101
30	Insulin/IGF-I Signaling Pathways Enhances Tumor Cell Invasion through Bisecting GlcNAc N-glycans Modulation. An Interplay with E-Cadherin. PLoS ONE, 2013, 8, e81579.	1.1	33
31	Canine tumors: a spontaneous animal model of human carcinogenesis. Translational Research, 2012, 159, 165-172.	2.2	208
32	Loss and Recovery of Mgat3 and GnT-III Mediated E-cadherin N-glycosylation Is a Mechanism Involved in Epithelial-Mesenchymal-Epithelial Transitions. PLoS ONE, 2012, 7, e33191.	1.1	93
33	Epithelial E- and P-cadherins: Role and clinical significance in cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1826, 297-311.	3.3	137
34	Modulation of E-cadherin function and dysfunction by N-glycosylation. Cellular and Molecular Life Sciences, 2011, 68, 1011-1020.	2.4	132
35	Molecular Carcinogenesis of Canine Mammary Tumors. Veterinary Pathology, 2011, 48, 98-116.	0.8	81
36	The role of N-acetylglucosaminyltransferase III and V in the post-transcriptional modifications of E-cadherin. Human Molecular Genetics, 2009, 18, 2599-2608.	1.4	100

#	Article	IF	CITATIONS
37	MUC1 expression in canine malignant mammary tumours and relationship to clinicopathological features. Veterinary Journal, 2009, 182, 491-493.	0.6	17
38	Role of E-cadherin N-glycosylation profile in a mammary tumor model. Biochemical and Biophysical Research Communications, 2009, 379, 1091-1096.	1.0	67
39	Molecular Plasticity of E-Cadherin and Sialyl Lewis X Expression, in Two Comparative Models of Mammary Tumorigenesis. PLoS ONE, 2009, 4, e6636.	1.1	15
40	Sialyl Lewis x expression in canine malignant mammary tumours: correlation with clinicopathological features and E-Cadherin expression. BMC Cancer, 2007, 7, 124.	1.1	28